Johnson & Johnson And Atlas Ventures Back Launch Of Drug Developer Using Epigenetics To Treat Alzheimer’s Disease

Circle Connections: New Products & Services Johnson & Johnson kicked off the launch of its Boston innovation center with news that it is backing a new drug developer targeting Alzheimer's disease and other neurological disorders. Early stage life science investor Atlas Ventures started Rodin Therapeutics with biotechnology company Proteros and secured backing from J&Js venture arm. Rodin is using epigenetics to develop therapeutics for Alzheimer's disease and other neurological disorders. Epigenetics focuses on changes in gene expression other than those caused by underlying DNA. It refers to external modifications to DNA that turn genes on or . . .